-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Monterey Bio Acquisition Co. (NASDAQ:MTRYW) Short Interest Update
Monterey Bio Acquisition Co. (NASDAQ:MTRYW) Short Interest Update
Monterey Bio Acquisition Co. (NASDAQ:MTRYW – Get Rating) was the target of a large growth in short interest during the month of December. As of December 15th, there was short interest totalling 37,400 shares, a growth of 80.7% from the November 30th total of 20,700 shares. Based on an average daily volume of 18,200 shares, the short-interest ratio is presently 2.1 days.
Monterey Bio Acquisition Stock Performance
MTRYW stock opened at $0.02 on Friday. Monterey Bio Acquisition has a fifty-two week low of $0.02 and a fifty-two week high of $0.41. The business's 50 day moving average price is $0.04 and its two-hundred day moving average price is $0.05.
Get Monterey Bio Acquisition alerts:Institutional Inflows and Outflows
An institutional investor recently bought a new position in Monterey Bio Acquisition stock. Ramius Advisors LLC purchased a new position in Monterey Bio Acquisition Co. (NASDAQ:MTRYW – Get Rating) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 286,110 shares of the company's stock, valued at approximately $27,000.
Monterey Bio Acquisition Company Profile
(Get Rating)Monterey Bio Acquisition Corporation focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. It intends to acquire businesses in the biotech industry. The company was formerly known as Chardan FinTech Acquisition Corp.
Featured Articles
- Get a free copy of the StockNews.com research report on Monterey Bio Acquisition (MTRYW)
- Is Kintara Therapeutics A Hidden Gem?
- Should You Warm up to Generac Stock for the Winter?
- 3 High-Yield Dividend Stocks to Hold for the Long Haul
- Cal-Maine Posts Record Quarter, Remain CALM Income Investors
- Tesla Stock: What the Bulls and the Bears Are Getting Wrong
Receive News & Ratings for Monterey Bio Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monterey Bio Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
Monterey Bio Acquisition Co. (NASDAQ:MTRYW – Get Rating) was the target of a large growth in short interest during the month of December. As of December 15th, there was short interest totalling 37,400 shares, a growth of 80.7% from the November 30th total of 20,700 shares. Based on an average daily volume of 18,200 shares, the short-interest ratio is presently 2.1 days.
蒙特雷生物收购公司(纳斯达克股票代码:MTRYW — Get Rating)是12月空头利率大幅增长的目标。截至12月15日,空头利率共计37,400股,较11月30日的20,700股增长了80.7%。根据18,200股的平均每日成交量,目前的空头利率为2.1天。
Monterey Bio Acquisition Stock Performance
蒙特雷生物收购股票表现
MTRYW stock opened at $0.02 on Friday. Monterey Bio Acquisition has a fifty-two week low of $0.02 and a fifty-two week high of $0.41. The business's 50 day moving average price is $0.04 and its two-hundred day moving average price is $0.05.
周五,MTRYW股票开盘价为0.02美元。蒙特雷生物收购创下五十二周低点0.02美元,五十二周高点为0.41美元。该公司的50天移动平均线价格为0.04美元,其两百天移动平均线价格为0.05美元。
Institutional Inflows and Outflows
机构流入和流出
An institutional investor recently bought a new position in Monterey Bio Acquisition stock. Ramius Advisors LLC purchased a new position in Monterey Bio Acquisition Co. (NASDAQ:MTRYW – Get Rating) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 286,110 shares of the company's stock, valued at approximately $27,000.
一位机构投资者最近购买了蒙特雷生物收购股票的新头寸。Ramius Advisors LLC收购了蒙特雷生物收购公司的新职位(纳斯达克股票代码:MTRYW — Get Rating)在向美国证券交易委员会提交的最新13F文件中表示,该公司在第二季度上涨。该机构投资者购买了该公司286,110股股票,价值约27,000美元。
Monterey Bio Acquisition Company Profile
蒙特雷生物收购公司简介
Monterey Bio Acquisition Corporation focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. It intends to acquire businesses in the biotech industry. The company was formerly known as Chardan FinTech Acquisition Corp.
蒙特雷生物收购公司专注于与一家或多家企业进行合并、资本证券交换、资产收购、股票购买、重组或相关业务合并。它打算收购生物技术行业的业务。该公司前身为查丹金融科技收购公司。
Featured Articles
精选文章
- Get a free copy of the StockNews.com research report on Monterey Bio Acquisition (MTRYW)
- Is Kintara Therapeutics A Hidden Gem?
- Should You Warm up to Generac Stock for the Winter?
- 3 High-Yield Dividend Stocks to Hold for the Long Haul
- Cal-Maine Posts Record Quarter, Remain CALM Income Investors
- Tesla Stock: What the Bulls and the Bears Are Getting Wrong
- 免费获取 StockNews.com 关于蒙特雷生物收购 (MTRYW) 的研究报告
- 金塔拉疗法是隐藏的宝石吗?
- 你应该为冬天的 Generac Stock 做热身吗?
- 3只高收益股息股票可供长期持有
- 加州缅因州公布创纪录的季度业绩,收益投资者保持冷静
- 特斯拉股票:多头和空头做错了什么
Receive News & Ratings for Monterey Bio Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monterey Bio Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
每天接收蒙特雷生物收购的新闻和评级 -在下面输入您的电子邮件地址,即可通过Marketbeat.com的免费每日电子邮件时事通讯接收蒙特雷生物收购及相关公司的最新新闻和分析师评级的简明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧